Hepatitis C virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine

Journal of Medical Virology

Volumn 79, Issue 2, 2007, Pages 144-154

  Castelain, S ^a   Bonte, D ^a   Penin, F ^b   Francois C ^a   Capron, D ^a   Dedeurwaerder, S ^a   Zawadzki, P ^a   Morel, V ^a   Wychowski, C ^c   Duverlie, G ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

Amantadine; Hepatitis C virus; p7 Protein; Therapy; Variability

Indexed keywords

AMANTADINE; AMINO ACID; HISTIDINE; INTERFERON; ION CHANNEL; PROTEIN P7; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACIDIFICATION; ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESPONSE; DRUG SPECIFICITY; ENDOSOME; FEMALE; FUNCTIONAL PROTEOMICS; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; MALE; MOLECULAR CLONING; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PH; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN VARIANT; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURAL PROTEOMICS; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; AMANTADINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VARIATION (GENETICS); VIRAL PROTEINS;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 33845965324     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20772     Document Type: Article

References (43)

1. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S. 2003. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: A placebo-controlled trial. Hepatology 37:1359-1367.
2. Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR. 2001. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: A UK multicentre study. J Hepatol 35:512-516.
3. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. 2002. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 76:3720-3730.
4. Carrere-Kremer S, Montpellier C, Lorenzo L, Brulin B, Cocquerel L, Belouzard S, Penin F, Dubuisson J. 2004. Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J Biol Chem 279: 41384-41392.
5. Castelain S, Khorsi H, Zawadzki P, Sueur JM, Capron JP, Eb F, Duverlie G. 1997. Direct blotting electrophoresis for sequencing and genotyping hepatitis C virus. J Virol Methods 65:237-243.
6. Castelain S, Khorsi H, Roussel J, Francois C, Jaillon O, Capron D, Penin F, Wychowski C, Meurs E, Duverlie G. 2002. Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity. J Infect Dis 185:573-583.
7. Chan J, O'Riordan K, Wiley TE. 2002. Amantadine's viral kinetics in chronic hepatitis C infection. Dig Dis Sci 47:438-442.
8. Ciampor F, Thompson CA, Grambas S, Hay AJ. 1992. Regulation of pH by the M2 protein of influenza A viruses. Virus Res 22:247-258.
9. Combet C, Penin F, Geourjon C, Deleage G. 2004. HCVDB: Hepatitis C virus sequences database. Appl Bioinformatics 3:237-240.
10. De Clercq E. 2001. Antiviral drugs: Current state of the art. J Clin Virol 22:73-89.
11. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. 1982. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 307:580-534.
12. Duff KC, Gilchrist PJ, Saxena AM, Bradshaw JP. 1994. Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel. Virology 202:287-293.
13. Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A. 2006. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 44:275-282.
14. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV. 2002. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 76:11440-11446.
15. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ. 2003. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535:34-38.
16. Griffin SD, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ. 2004. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 85:451-461.
17. Harada T, Tautz N, Thiel HJ. 2000. E2-p7 region of the bovine viral diarrhea virus polyprotein: Processing and functional studies. J Virol 74:9498-9506.
18. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. 1994. Influenza A virus M2 ion channel protein: A structure-function analysis. J Virol 68: 1551-1563.
19. Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Nagao K, Saisho H. 2005. Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 331:621-629.
20. Kimura M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111-120.
21. Kobayashi M, Bennett MC, Bercot T, Singh IR. 2006. Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay. J Virol 80:1817-1825.
22. Kumar S, Tamura K, Jakobsen IB, Nei M. 2001. MEGA2: Molecular evolutionary genetics analysis software. Bioinformatics 17:1244-1245.
23. Lake-Bakaar G, Ruffini L, Kuzmic P. 2003. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 48:126-139.
24. Lavillette D, Bartosch B, Nourrisson D, Verney G, Cosset FL, Penin F, Pecheur EI. 2006. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem 281: 3909-3917.
25. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. 1994. Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini. J Virol 68:5063-5073.
26. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, Carretta V, Bacca D, Giangaspero A, Bisceglia M, Ventrella F, Dell'Erba G, Andriulli A. 2001. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 33:989-993.
27. Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, Adeleine P, Trepo C. 2006. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 44:484-490.
28. Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. 1994. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J Virol 68:2731-2734.
29. Okada A, Miura T, Takeuchi H. 2001. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel from influenza a virus. Biochemistry 40:6053-6060.
30. Patargias G, Zitzmann N, Dwek R, Fischer WB. 2006. Protein-protein interactions: Modeling the hepatitis C virus ion channel p7. J Med Chem 49:648-655.
31. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, Zitzmann N. 2003. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA 100:6104-6108.
32. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. 1998. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations. J Virol 72:2795-2805.
33. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. 2004. Structural biology of hepatitis C virus. Hepatology 39:5-19.
34. Premkumar A, Wilson L, Ewart GD, Gage PW. 2004. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 557:99-103.
35. Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH, Bukh J. 2003. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 100:11646-11651.
36. Salom D, Hill BR, Lear JD, DeGrado WF. 2000. pH-dependent tetramerization and amantadine binding of the transmembrane helix of M2 from the influenza A virus. Biochemistry 39:14160-14170.
37. Smith JP. 1997. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681-1687.
38. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680.
39. Thuluvath PJ, Maheshwari A, Mehdi J, Fairbanks KD, Wu LL, Gelrud LG, Ryan MJ, Anania FA, Lobis IF, Black M. 2004. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut 53:130-135.
40. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. 2006. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80:1734-1741.
41. Wang C, Lamb RA, Pinto LH. 1995. Activation of the M2 ion channel of influenza virus: A role for the transmembrane domain histidine residue. Biophys J 69:1363-1371.
42. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542.
43. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. 2000. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32:835-341.